European Medicines Agency workshop on longer term outcomes

Activity: Internal positions, career professional development and otherOtherResearch


This was a two day meeting in which I was invited to give a talk on the lessons learnt from the situation with sodium valproate to inform future pharmacovigilance initiatives. I additionally contributed to general discussions about how longer term outcomes following medication exposures should be handled within the current regulator framework. The EMA plans to draft a paper as the outcome for this meeting which will outline the future of post-market pharmacovigilance with regards to use of medications in pregnancy and the childbearing years.
PeriodJun 2018
Degree of RecognitionInternational


  • pharmacovigilance
  • Neurodevelopment
  • Teratology